The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the potential efficacy of JNJ-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers.

Key facts

Study ID

NCT01826786

Run by

Janssen Research & Development, LLC

People needed

43

Starts

2013-08-01

Expected to finish

2014-08-01

Last updated by the study team

2014-10-15

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Good general health
• Body mass index between 18 and 30 kg/m2 and body weight not less than 50 kg
• Must adhere to required contraception during and for 3 months after study
• Must agree to not donate sperm during and for 3 months after study
• Must agree to not donate blood during and for 1 month after study
• Able to speak and understand English fluently

You may not qualify if…

• Clinically significant medical or psychiatric illness
• Any contraindication to magnetic resonance imaging
• Unable to pass hearing test
• Alcohol or substance abuse; excessive nicotine or caffeine use
• Recently received an investigational drug, vaccine, or invasive medical device
• Unable to abide by protocol restrictions on use of other medications

Where it is running

• Study site — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.